Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...
A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral probiotic yeast to do the work for them, with the fungal cells able to release ...
CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, ...
Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...
- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA ® or OPDIVO ® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in the tumor ...
MedPage Today on MSN
PD-1 inhibitor raises PFS in advanced acral melanoma
First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but statistically significant increase in progression-free survival (PFS) compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback